Երկիր: Կանադա
Լեզու: անգլերեն
Աղբյուրը: Health Canada
DROSPIRENONE; LEVOMEFOLATE CALCIUM; LEVOMEFOLATE CALCIUM; ETHINYL ESTRADIOL
BAYER INC
G03AA12
DROSPIRENONE AND ESTROGEN
3.0MG; 0.451MG; 0.451MG; 0.03MG
TABLET
DROSPIRENONE 3.0MG; LEVOMEFOLATE CALCIUM 0.451MG; LEVOMEFOLATE CALCIUM 0.451MG; ETHINYL ESTRADIOL 0.03MG
ORAL
28
Prescription
CONTRACEPTIVES
Active ingredient group (AIG) number: 0453183002; AHFS:
APPROVED
2015-06-18
_ _ _YASMIN PLUS Product Monograph _ _ _ _Page 1 of 70 _ _ _ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR YASMIN ® PLUS 3.0 mg drospirenone, 0.030 mg ethinyl estradiol, 0.451 mg levomefolate calcium tablets and 0.451 mg levomefolate calcium tablets Oral Contraceptive Acne Therapy Improvement in Folate Status Bayer Inc. 2920 Matheson Boulevard East Mississauga, Ontario L4W 5R6 http://www.bayer.ca Date of Revision: March 2, 2017 Submission Control No: 200982 © 2017, Bayer Inc. ® TM see www.bayer.ca/tm-mc _ _ _YASMIN PLUS Product Monograph _ _ _ _Page 2 of 70 _ _ _ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ..........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 INDICATIONS AND CLINICAL USE ..............................................................................3 CONTRAINDICATIONS ...................................................................................................3 WARNINGS AND PRECAUTIONS ..................................................................................4 ADVERSE REACTIONS ..................................................................................................13 DRUG INTERACTIONS ..................................................................................................19 DOSAGE AND ADMINISTRATION ..............................................................................26 OVERDOSAGE ................................................................................................................29 ACTION AND CLINICAL PHARMACOLOGY ............................................................29 STORAGE AND STABILITY ..........................................................................................36 SPECIAL HANDLING INSTRUCTIONS .......................................................................36 DOSAGE FORMS, COMPOSITION AND PACKAGING .............................................36 PART II: SCIENTIFIC INFORMAT Կարդացեք ամբողջական փաստաթուղթը